{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Astria Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ATXS"},"Address":{"label":"Address","value":"100 HIGH STREET 28TH FLOOR, BOSTON, Massachusetts, 2110, United States"},"Phone":{"label":"Phone","value":"+1 617 349-1971"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema."},"CompanyUrl":{"label":"Company Url","value":"https://www.astriatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew Nichols","title":"Chief Scientific Officer"},{"name":"Jill C. Milne","title":"President, Chief Executive Officer &amp; Director"},{"name":"Maria C. Mancini","title":"Vice President-Clinical Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}